{"component": "definition", "props": {"groups": [{"snippet_links": [], "snippet": "has the meaning set forth in Section 1.3(a).", "size": 8, "samples": [{"hash": "bCtBnHWh8eH", "uri": "/contracts/bCtBnHWh8eH#first-milestone", "label": "Purchase and Sale Agreement (Galera Therapeutics, Inc.)", "score": 30.7741279602, "published": true}, {"hash": "lsmYQLURqGp", "uri": "/contracts/lsmYQLURqGp#first-milestone", "label": "Purchase and Sale Agreement (Galera Therapeutics, Inc.)", "score": 30.3059539795, "published": true}, {"hash": "bM1XihSid9E", "uri": "/contracts/bM1XihSid9E#first-milestone", "label": "Purchase and Sale Agreement", "score": 26.1704311371, "published": true}], "hash": "328f873fa8a43b566d65067a8b6c2f5e", "id": 1}, {"snippet_links": [{"key": "the-network", "type": "definition", "offset": [46, 57]}, {"key": "token-functionality", "type": "clause", "offset": [75, 94]}, {"key": "by-participants", "type": "clause", "offset": [143, 158]}], "snippet": "means that Blockstack has succeeded in making the Network operational with Token functionality and the Network is live and being actively used by participants.", "size": 6, "samples": [{"hash": "7BuZFP8xlkP", "uri": "/contracts/7BuZFP8xlkP#first-milestone", "label": "Limited Partnership Agreement (Blockstack Inc.)", "score": 30.5140323639, "published": true}, {"hash": "63Cbc1Egvg6", "uri": "/contracts/63Cbc1Egvg6#first-milestone", "label": "Limited Partnership Agreement (Blockstack Inc.)", "score": 30.5140323639, "published": true}, {"hash": "3A52NeGwPSx", "uri": "/contracts/3A52NeGwPSx#first-milestone", "label": "Limited Partnership Agreement (Blockstack Inc.)", "score": 30.5140323639, "published": true}], "hash": "ef9d2c613887ac18e72b8fce65cf86b1", "id": 2}, {"snippet_links": [], "snippet": "means [***].", "size": 4, "samples": [{"hash": "k902QvC3KNc", "uri": "/contracts/k902QvC3KNc#first-milestone", "label": "Asset Purchase Agreement (Intermune Inc)", "score": 21.0, "published": true}], "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 3}, {"snippet_links": [], "snippet": "means **.", "size": 3, "samples": [{"hash": "36wQEeI7P2f", "uri": "/contracts/36wQEeI7P2f#first-milestone", "label": "Stock Purchase Agreement (Biota Pharmaceuticals, Inc.)", "score": 26.3470230103, "published": true}, {"hash": "j2W2JdK5Ne", "uri": "https://investors.vaxart.com/static-files/66b01ef5-aa72-4399-925c-7b13a3f00c71", "label": "investors.vaxart.com", "score": 9.96235466, "published": false}, {"hash": "i00h3ZWx45L", "uri": "https://investors.aviragentherapeutics.com/static-files/66b01ef5-aa72-4399-925c-7b13a3f00c71", "label": "investors.aviragentherapeutics.com", "score": 9.5653657913, "published": false}], "hash": "9716ed9e370d1b12563c408480758ae1", "id": 4}, {"snippet_links": [{"key": "second-milestone", "type": "clause", "offset": [3, 19]}, {"key": "third-milestone", "type": "definition", "offset": [22, 37]}, {"key": "fourth-milestone", "type": "clause", "offset": [41, 57]}, {"key": "fifth-milestone", "type": "definition", "offset": [61, 76]}], "snippet": ", \"Second Milestone\", Third Milestone\", \"Fourth Milestone\", \"Fifth Milestone\", and \"Sixth Milestone\", respectively.", "size": 3, "samples": [{"hash": "fC6zFmG5r7L", "uri": "/contracts/fC6zFmG5r7L#first-milestone", "label": "Option Agreement (B Twelve Inc)", "score": 18.0, "published": true}, {"hash": "93244Mi2d7F", "uri": "/contracts/93244Mi2d7F#first-milestone", "label": "Option Agreement (B Twelve Inc)", "score": 18.0, "published": true}], "hash": "baaeb2161c0e6c93a6896210415cf22f", "id": 5}, {"snippet_links": [], "snippet": "has the meaning set forth in Section 2.6(b)(i).", "size": 3, "samples": [{"hash": "39SnikobqzV", "uri": "/contracts/39SnikobqzV#first-milestone", "label": "Asset Purchase Agreement (Nabi  Biopharmaceuticals)", "score": 21.0, "published": true}], "hash": "e3db0930911a6bbe8aa8bb7d43419219", "id": 6}, {"snippet_links": [{"key": "by-parent", "type": "clause", "offset": [14, 23]}, {"key": "fda-approval", "type": "definition", "offset": [76, 88]}, {"key": "cvr-product", "type": "definition", "offset": [97, 108]}], "snippet": "means receipt by Parent or one of its Affiliates or their (sub)licensees of FDA Approval for any CVR Product for any galactosemia indication.", "size": 2, "samples": [{"hash": "ksc6smcxD5D", "uri": "/contracts/ksc6smcxD5D#first-milestone", "label": "Contingent Value Rights Agreement (AT2B, Inc.)", "score": 37.09034729, "published": true}, {"hash": "iIRmAEMn6gF", "uri": "/contracts/iIRmAEMn6gF#first-milestone", "label": "Contingent Value Rights Agreement (Applied Therapeutics, Inc.)", "score": 36.9452438354, "published": true}], "hash": "2fb48d171d122fbae45481fdead43ffd", "id": 7}, {"snippet_links": [{"key": "annex-a", "type": "clause", "offset": [33, 40]}, {"key": "first-milestone-payment", "type": "definition", "offset": [79, 102]}], "snippet": "means the milestone set forth on Annex A under the heading \u201cFirst Milestone.\u201d \u201cFirst Milestone Payment\u201d has the meaning set forth in Annex A.", "size": 2, "samples": [{"hash": "ewVXxNAc5SC", "uri": "https://investors.abeonatherapeutics.com/all-sec-filings/content/0001144204-15-049914/0001144204-15-049914.pdf", "label": "investors.abeonatherapeutics.com", "score": 9.1273097992, "published": false}, {"hash": "2mX69Bn9klF", "uri": "https://investors.abeonatherapeutics.com/all-sec-filings/content/0001144204-15-049282/0001144204-15-049282.pdf", "label": "investors.abeonatherapeutics.com", "score": 9.1273097992, "published": false}], "hash": "980395caecc5fa7fc7edcb9049fe3a51", "id": 8}, {"snippet_links": [{"key": "milestone-1", "type": "definition", "offset": [110, 121]}, {"key": "sales-milestone", "type": "definition", "offset": [141, 156]}], "snippet": "means the achievement of all First Milestone Components. \u201cFirst Milestone Component\u201d means each of Automation Milestone 1, Cost Milestone 1, Sales Milestone 1 or Technology Milestone 1.", "size": 2, "samples": [{"hash": "4yP4jQXJKkA", "uri": "/contracts/4yP4jQXJKkA#first-milestone", "label": "Fourth Amendment to Credit and Guaranty Agreement (Eos Energy Enterprises, Inc.)", "score": 33.5756340027, "published": true}, {"hash": "iSB5MBpIrb0", "uri": "/contracts/iSB5MBpIrb0#first-milestone", "label": "First Amendment to Credit and Guaranty Agreement (Eos Energy Enterprises, Inc.)", "score": 33.3429145813, "published": true}], "hash": "562f8e4d15fb0c0f7b51db6c56dd303e", "id": 9}, {"snippet_links": [{"key": "first-patient-in", "type": "definition", "offset": [35, 51]}, {"key": "first-clinical-trial", "type": "definition", "offset": [56, 76]}, {"key": "product-candidate", "type": "definition", "offset": [83, 100]}, {"key": "multiple-sclerosis", "type": "clause", "offset": [176, 194]}, {"key": "a-phase", "type": "clause", "offset": [248, 255]}, {"key": "clinical-study", "type": "definition", "offset": [269, 283]}, {"key": "phase-ib", "type": "definition", "offset": [358, 366]}, {"key": "phase-ii", "type": "definition", "offset": [370, 378]}, {"key": "covered-by", "type": "definition", "offset": [419, 429]}, {"key": "intellectual-property-right", "type": "clause", "offset": [434, 461]}, {"key": "by-the-company", "type": "clause", "offset": [527, 541]}], "snippet": "is as follows: \u00b7 The dosing of the first patient in the first clinical trial for a product candidate, other than any clinical trial of RPC1063 (the Company\u2019s S1P1 agonist) for multiple sclerosis, where: (i) such clinical trial would be regarded as a Phase I, II or III clinical study (as defined in 21 C.F.R. \u00a7312.21(a), (b) or (c)), or any hybrid such as a Phase Ib or Phase II/III; and (ii) such product candidate is covered by any intellectual property right held (whether owned, co-owned, licensed or otherwise controlled) by the Company.", "size": 2, "samples": [{"hash": "k9qC45GfLTK", "uri": "/contracts/k9qC45GfLTK#first-milestone", "label": "Restricted Stock Issuance Agreement (Receptos, Inc.)", "score": 24.2553043365, "published": true}, {"hash": "4GlUltjg31S", "uri": "/contracts/4GlUltjg31S#first-milestone", "label": "Restricted Stock Issuance Agreement (Receptos, Inc.)", "score": 24.1184120178, "published": true}], "hash": "2bacf7e473e8108e2c1eaaa06ba262dc", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYZmlyc3QtbWlsZXN0b25lIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "First Milestone", "snippet": "has the meaning set forth in Section 1.3(a).", "size": 106, "id": "first-milestone", "examples": ["Until the date of the Additional Issuance upon the achievement of the <strong>First Milestone</strong>, \u2587\u2587\u2587\u2587\u2587\u2019s Board of Directors shall not appoint additional Directors to exceed the Number of Directors."], "related": [["development-milestone", "Development Milestone", "Development Milestone"], ["milestone-1", "Milestone 1", "Milestone 1"], ["performance-milestone", "Performance Milestone", "Performance Milestone"], ["project-milestone", "Project Milestone", "Project Milestone"], ["milestone-date", "Milestone Date", "Milestone Date"]], "related_snippets": [], "updated": "2026-05-02T06:01:41+00:00"}, "json": true, "cursor": ""}}